Key result
The 50% inhibitory concentrations in the EXCA-1 assay were 0.025 IU/ml for dalteparin, 0.13 U/ml for danaparoid, 0.12 IU/ml for heparin, 1.3 microg/ml for fondaparinux, 2.4 ng/ml for hirudin, and 1 microg/ml for argatroban.
Why the study?
Can the extrinsic coagulation activity assay (EXCA) monitor the efficiency of various plasmatic anticoagulants in normal plasma?
Can the extrinsic coagulation activity assay (EXCA) monitor the efficiency of various plasmatic anticoagulants in normal plasma?
The extrinsic coagulation activity assay (EXCA) can effectively monitor the efficiency of clinically used plasmatic anticoagulants by determining their 50% inhibitory concentrations.
Answers are grounded in this paper and cite their sources.
EXCA may monitor anticoagulant efficiency in plasma; hypothesis-generating and should not yet change practice.
Six thrombin-generation inhibitors or thrombin inhibitors were compared in the extrinsic coagulation activity assay (EXCA), where the normal thrombin generation is about 1 IU/ml within 1 min (37 degrees C). Unfrozen pooled normal citrated plasma was supplemented on flat-bottom wells (23 degrees C) with increasing concentrations of dalteparin, danaparoid, heparin, fondaparinux, hirudin, or argatroban. To 50 microl plasma, 5 microl of 1.5 ng/ml tissue factor, 6% bovine serum albumin, and 250 mmol/l CaCl2 were added. After 1 and 2 min coagulation reaction time at 37 degrees C (EXCA-1 and EXCA-2), 100 microl of 2.5 mol/l arginine and 0.16% Triton X 100, pH 8.6, were added. After 3 min (23 degrees C), 25 microl of 1 mmol/l CHG-Ala-Arg-pNA in 1.25 mol/l arginine, pH 8.7, were added, and the linear increase in absorbance with time was determined at 405 nm. The 50% inhibitory concentrations of plasmatic anticoagulants tested in the EXCA-1 (37 degrees C) were 0.025 IU/ml dalteparin, 0.13 U/ml danaparoid, 0.12 IU/ml heparin, 1.3 microg/ml fondaparinux, 2.4 ng/ml hirudin, and 1 microg/ml argatroban. From the 50% inhibitory concentration of hirudin it can be concluded that inhibition of about 30 mIU/ml thrombin halves the normal EXCA-1 value (i.e. if about 0.1 IU/ml thrombin are inactivated, then thrombin cannot self-amplify its generation 10-fold). The efficiency of any clinically used plasmatic anticoagulant can be monitored in the EXCA.
No takes yet. Share an insight, caveat, or question.
T. Stief (2007) studied this question. dalteparin, danaparoid, heparin, fondaparinux, hirudin, or argatroban was evaluated on 50% inhibitory concentrations in EXCA-1. The 50% inhibitory concentrations in the EXCA-1 assay were 0.025 IU/ml for dalteparin, 0.13 U/ml for danaparoid, 0.12 IU/ml for heparin, 1.3 microg/ml for fondaparinux, 2.4 ng/ml for hirudin, and 1 microg/ml for argatroban.
Synapse has enriched 10 related papers. Consider them for comparative context: